Ikena Oncology

IK-175 Clin1 bladder cancer (Partner: BMS), Clin1 head & neck cancer (partner: BMS); IK-595 Clin0 oncology; 2 undisclosed programs Clin0 oncology

Ikena Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies intended to enable a personalized approach for every patient with cancer. The company's pipeline includes programs that target key signaling pathways that drive the formation and spread of cancer, as well as programs targeting the tumor microenvironment. Ikena's lead product candidate, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway. The Hippo signaling pathway plays a critical role in regulating cell growth and survival. When the Hippo signaling pathway is disrupted, cancer cells can grow and spread uncontrollably. Ikena also has a number of other programs in preclinical and early clinical development.

Jobs: